Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
histrelin · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| one histrelin acetate 50 mg implant | EXPERIMENTAL | The test product was a histrelin acetate 50 mg hydrogel implant surgically placed subdermally into the inner aspect of the upper arm. |
| Name | Type | Description |
|---|---|---|
| histrelin acetate | DRUG | 52 week implant |
Key Inclusion Criteria: * Male Age 45 or older * Histologically confirmed adenocarcinoma of the prostate * Disease Staging III or IV * Clinical indication for androgen suppression therapy * Serum testosterone at least 150 ng/dL at screening * WHO Performance Scale 0 to 3 * Life expectancy of at lea...
Top 20 of 53 competitors
Histrelin is a small molecule being studied for the treatment of advanced prostate cancer, specifically adenocarcinoma of the prostate. It is administered as a subdermal implant and is currently in Phase 3 clinical development for this indication.
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist. It works by suppressing the production of testosterone, which can help slow the growth of prostate cancer cells that depend on this hormone to proliferate.
Histrelin is being developed by BrainsWay Ltd., a company publicly traded under the ticker symbol BWAY. The drug is currently in Phase 3 clinical trials for the treatment of advanced prostate cancer.
Histrelin is in Phase 3 clinical development. A Phase 3 study evaluating the efficacy and safety of the histrelin subdermal implant in men with advanced prostate cancer has been completed.
Histrelin has been studied in a Phase 3 clinical trial identified as NCT01697384, titled "Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer." This trial enrolled 138 male participants aged 45 years and older and has been completed.